Whalesbook
Financial Performance Under Pressure Despite Growth
Neogen Chemicals Limited kicked off 2026 by posting a 9% year-on-year increase in revenue for the third quarter ending December 31, 2025, reaching ₹220 crore. This top-line growth was driven by a 6% rise in organic chemicals revenue to ₹187 crore and a significant 35% surge in inorganic chemicals revenue to ₹33 crore. However, the company's profitability took a hit, with profit after tax (PAT) plummeting by 63% to ₹4 crore compared to ₹10 crore in Q3 FY25.
The Profit Squeeze: Costs Bite into Earnings
The sharp decline in PAT was largely due to elevated finance costs, which rose 60% year-on-year to ₹21.51 crore, stemming from capital expenditure for the reconstruction of the Dahej plant and expansionary spending in its battery chemicals division, Neogen Ionics. Furthermore, EBITDA saw an 8% dip to ₹31.9 crore, with margins contracting to 14.5% from 17.2% in the prior year's quarter. Management cited transient costs from the Neogen Ionics ramp-up and increased operational expenses related to the Dahej fire incident and interim toll manufacturing as key factors impacting performance.
Dahej Fire Recovery Gains Momentum
The company continues to navigate the aftermath of the March 5, 2025, fire at its Dahej SEZ facility. As of the nine months ending December 2025, Neogen has received ₹83.48 crore in insurance claims, with a net claim receivable standing at ₹251.12 crore. The reconstruction of the Dahej plant is progressing rapidly, with commissioning anticipated in Q1 FY27. To mitigate disruptions, interim production has been successfully shifted to other company sites, and a significant portion of the expected fund inflows, including insurance claims, will support rebuilding efforts.
Strategic Pivot to Battery Chemicals
Neogen is making bold strides in the burgeoning battery chemicals sector. A key development is the formation of a joint venture, Neogen Morita New Materials Limited, with Japan's Morita Investment Limited. This JV, in which Neogen holds an 80% stake, aims to produce LiPF6 salt globally using proven Japanese technology and is positioned as India's only non-FEOC compliant electrolyte salt plant [cite: input text].
The company is also on track with its Pakhajan Greenfield Project, targeting commercial production of electrolyte by H1 FY27 and electrolyte salts by H2 FY27. A long-term commercial supply approval has already been secured from a major Indian battery manufacturer, signalling strong market validation.
Management has reiterated its FY27 revenue guidance of ₹400-500 crore for battery chemicals, with the base business expected to grow at double-digit rates. The CDMO and advanced intermediates segment is also poised for significant expansion, aiming for a run-rate of ₹950 crore for FY26 [cite: input text].
Financial Health and Funding Outlook
As of December 2025, Neogen's consolidated net debt stood at ₹1,175 crore, with a Debt to Equity ratio of 1.55 times. The company anticipates approximately ₹550 crore in fund inflows over the next six months from insurance claims, the Morita JV investment, and a promoter preferential issue, which will bolster its financial position to fund ongoing projects and expansion plans.
Risks and Outlook
While the strategic shift towards battery chemicals presents significant growth opportunities, execution risks remain as new plants are commissioned and supply agreements are secured. The competitive landscape in battery materials is intensifying, with several Indian players also expanding their offerings. The company's ability to manage increased debt levels and successfully ramp up new capacities will be crucial. The forward view remains optimistic, with Neogen Ionics expected to enhance its margin profile and diversify revenue, positioning the company to capitalize on the evolving electric vehicle and energy storage ecosystems.
Peer Comparison
Neogen Chemicals is strategically positioning itself against established and emerging players in India's specialty chemical and battery materials market. Companies like Himadri Speciality Chemical, Gujarat Fluorochemicals, and Tatva Chintan Pharma Chem are also investing heavily in battery-related chemicals and materials. While Himadri is focusing on anode materials and Tatva Chintan on electrolyte salts, Neogen's Indo-Japan JV for LiPF6 production and its Pakhajan project for electrolytes and salts aim to capture a significant share of the rapidly growing electrolyte and salt market. Unlike some larger conglomerates entering the fray, Neogen's focused approach on niche specialty chemicals, now amplified by its battery division, distinguishes its strategy. Its Q3 performance, though impacted by costs, shows sustained revenue growth, a key metric as the sector expands. The company's dependence on ramping up its new battery chemical facilities will be a critical factor in its future growth compared to peers.